Summary
CONTIPHARMA has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €3.2m and a net result of €1.1m. Equity is shrinking by about 2.7% per year across the filed financial years. Its solvency ranks better than 49% of 6,116 sector peers (NACE 46, financial year 2025). The company has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Directors
No directors read yet: 0 of 7 Gazette acts processed. See the directors and other office holders in the KBO →
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.